Homestead Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $130M | Buy |
516,501
+77,100
| +18% | +$16.6M | 3.23% | 5 |
|
|
2026
Q1 | $95.3M | Sell |
439,401
-91,300
| -17% | -$20.3M | 2.56% | 9 |
|
|
2025
Q4 | $121M | Sell |
530,701
-125,559
| -19% | -$28.6M | 3.21% | 6 |
|
|
2025
Q3 | $152M | Sell |
656,260
-57,600
| -8% | -$11.7M | 3.62% | 2 |
|
|
2025
Q2 | $133M | Buy |
713,860
+1,200
| +0.2% | +$223K | 3.14% | 4 |
|
|
2025
Q1 | $149M | Hold |
712,660
| – | – | 3.66% | 2 |
|
|
2024
Q4 | $127M | Buy |
712,660
+26,800
| +4% | +$4.93M | 3.05% | 7 |
|
|
2024
Q3 | $135M | Sell |
685,860
-500
| -0.1% | -$93.3K | 3.22% | 5 |
|
|
2024
Q2 | $118M | Sell |
686,360
-12,100
| -2% | -$2M | 2.9% | 8 |
|
|
2024
Q1 | $127M | Sell |
698,460
-1,100
| -0.2% | -$190K | 2.98% | 5 |
|
|
2023
Q4 | $108M | Sell |
699,560
-45,800
| -6% | -$6.68M | 2.77% | 7 |
|
|
2023
Q3 | $111M | Sell |
745,360
-121,127
| -14% | -$17.8M | 3.09% | 6 |
|
|
2023
Q2 | $120M | Buy |
866,487
+79,627
| +10% | +$11.7M | 3.18% | 8 |
|
|
2023
Q1 | $125M | Sell |
786,860
-17,000
| -2% | -$2.6M | 3.5% | 3 |
|
|
2022
Q4 | $130M | Sell |
803,860
-22,500
| -3% | -$3.45M | 3.47% | 3 |
|
|
2022
Q3 | $111M | Sell |
826,360
-3,700
| -0.4% | -$531K | 3.36% | 6 |
|
|
2022
Q2 | $127M | Hold |
830,060
| – | – | 3.6% | 5 |
|
|
2022
Q1 | $135M | Buy |
830,060
+12,700
| +2% | +$1.84M | 3.29% | 6 |
|
|
2021
Q4 | $111M | Sell |
817,360
-6,300
| -0.8% | -$744K | 2.55% | 10 |
|
|
2021
Q3 | $88.8M | Buy |
823,660
+3,200
| +0.4% | +$366K | 2.16% | 14 |
|
|
2021
Q2 | $92.4M | Buy |
820,460
+5,900
| +0.7% | +$664K | 2.14% | 13 |
|
|
2021
Q1 | $88.2M | Buy |
814,560
+49,000
| +6% | +$5.24M | 2.11% | 13 |
|
|
2020
Q4 | $82M | Sell |
765,560
-18,500
| -2% | -$1.78M | 2.03% | 14 |
|
|
2020
Q3 | $68.7M | Buy |
784,060
+15,200
| +2% | +$1.43M | 1.88% | 16 |
|
|
2020
Q2 | $75.5M | Buy |
768,860
+303,498
| +65% | +$26.7M | 1.94% | 17 |
|
|
2020
Q1 | $35.5M | Buy |
+465,362
| New | +$39.6M | 1.05% | 38 |
|
|
2017
Q1 | – | Sell |
-1,681,000
| Closed | -$105M | – | 96 |
|
|
2016
Q4 | $105M | Sell |
1,681,000
-408,281
| -20% | -$24.9M | 1.66% | 22 |
|
|
2016
Q3 | $132M | Hold |
2,089,281
| – | – | 2.18% | 11 |
|
|
2016
Q2 | $129M | Hold |
2,089,281
| – | – | 2.22% | 12 |
|
|
2016
Q1 | $119M | Buy |
+2,089,281
| New | +$116M | 2.13% | 15 |
|
Other funds holding ABBV
Homestead Advisers's ABBV Position: Q2 2026 in Review
Homestead Advisers increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $16.6M and bringing the position to 516,501 shares worth $130M. The position accounts for 3.23% of the portfolio, ranked #5.
Homestead Advisers first reported a position in ABBV in Q1 2016 and has held it in 30 quarters since. The position peaked at $152M in Q3 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Homestead Advisers held 516,501 shares of AbbVie worth $130M as of Q2 2026.
- Homestead Advisers bought 77,100 AbbVie shares in Q2 2026, an estimated $16.6M.
- AbbVie made up 3.23% of Homestead Advisers's portfolio in Q2 2026, its #5 holding.
- Homestead Advisers first reported a position in AbbVie in Q1 2016 and has held it in 30 quarters since.
- Homestead Advisers's AbbVie position peaked at $152M in Q3 2025.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Homestead Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.